Does HPV Type Affect Outcome in Oropharyngeal Cancer?
Overview
Otorhinolaryngology
Authors
Affiliations
Background: An epidemic of human papillomavirus (HPV)-related oropharyngeal squamous cell cancer (OPSCC) has been reported worldwide largely due to oral infection with HPV type-16, which is responsible for approximately 90% of HPV-positive cases. The purpose of this study was to determine the rate of HPV-positive oropharyngeal cancer in Southwestern Ontario, Canada.
Methods: A retrospective search identified ninety-five patients diagnosed with OPSCC. Pre-treatment biopsy specimens were tested for p16 expression using immunohistochemistry and for HPV-16, HPV-18 and other high-risk subtypes, including 31,33,35,39,45,51,52,56,58,59,67,68, by real-time qPCR.
Results: Fifty-nine tumours (62%) were positive for p16 expression and fifty (53%) were positive for known high-risk HPV types. Of the latter, 45 tumors (90%) were identified as HPV-16 positive, and five tumors (10%) were positive for other high-risk HPV types (HPV-18 (2), HPV-67 (2), HPV-33 (1)). HPV status by qPCR and p16 expression were extremely tightly correlated (p < 0.001, Fishers exact test). Patients with HPV-positive tumors had improved 3-year overall (OS) and disease-free survival (DFS) compared to patients with HPV-negative tumors (90% vs 65%, p = 0.001; and 85% vs 49%, p = 0.005; respectively). HPV-16 related OPSCC presented with cervical metastases more frequently than other high-risk HPV types (p = 0.005) and poorer disease-free survival was observed, although this was not statistically significant.
Conclusion: HPV-16 infection is responsible for a significant proportion of OPSCC in Southwestern Ontario. Other high-risk subtypes are responsible for a smaller subset of OPSCC that present less frequently with cervical metastases and may have a different prognosis.
Wotman M, Ivic-Pavlicic T, Westra W, Gold B, DAndrea M, Genden E Oncologist. 2024; 29(11):966-977.
PMID: 39137148 PMC: 11546636. DOI: 10.1093/oncolo/oyae202.
Rujan S, Bertesteanu S, Grigore R, Popescu B, Condeescu-Cojocarita M, Alexandru N J Pers Med. 2024; 14(3).
PMID: 38541025 PMC: 10971356. DOI: 10.3390/jpm14030283.
HPV16 Intratypic Variants in Head and Neck Cancers: A North American Perspective.
Gameiro S, Salnikov M, Zeng P, Barrett J, Nichols A, Mymryk J Viruses. 2023; 15(12).
PMID: 38140652 PMC: 10747106. DOI: 10.3390/v15122411.
Shenker R, Razavian N, DAgostino Jr R, Mowery Y, Brizel D, Hughes R Oral Oncol. 2023; 148:106644.
PMID: 38006690 PMC: 10843598. DOI: 10.1016/j.oraloncology.2023.106644.
Impact of HR-HPV infection on oncological outcomes in early cervical cancer.
Su X, Liu P, Zhao H, Sun L, Wang W, Jin S Front Oncol. 2023; 13:1264114.
PMID: 37700831 PMC: 10493382. DOI: 10.3389/fonc.2023.1264114.